Reliable, ergonomic and sustainable Surgical Instruments
The history of HASA Optix Belgium begun in 2012 with a dream to satisfy the individual needs of eye surgeons. This dream started to become a reality when prototype of our first single use ophthalmic instruments could not be differentiated from instruments by experienced surgeons.
Coming out of the COVID crisis, hospitals are facing the challenge of investing in quality equipment and controlling costs at the same time. From single location hospitals to clinic groups, we are extremely proud to have been able through our distributors to contribute to help hospitals to reach these two goals.
As an independent, privately owned company, our culture is far-removed from any short-term logic and is very much about building the future of ophthalmology with the new generation of surgeons and nurses who want to improve their quality of life as much as they want to deliver the best care possible. For our surgeons and nurses, we make the promise to keep concentrating our energy in simplifying ophthalmic surgery.
No matter where in the world you are based, our representative is close by.
We deliver to all corners of the world.
Hasa Optix Belgium exists to develop the products that will offer all stakeholders involved in ophtalmic surgery (surgeons, nurses, hospitals and patients) sustainable solutions contributing to a better cost-controlled work environment for an increased quality of care.
Additionally, cataracts being a leading cause of blindness in the world, according to the World Health Organization, we want to contribute to programs helping patients who can’t afford a cataract operation to be cured.
Quality improvement and cost savings are of great importance in healthcare in general and in ophthalmic surgery in particular.
Hospitals more than ever have to face the challenge of working profitably and obtaining optimum quality at the same time.
In a changing world, we believe there are new ways that will allow facilitating work of all stakeholders involved allowing a higher pharma-economic value.